Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Pharmaceutical Statistics
|
January 7, 2020
Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs
Claire L Smith, Zachary Thomas, Nathan Enas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
Yun Oh, Roy S Herbst, Howard Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2005
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors
Gary K Schwartz, Aaron Weitzman, Eileen O'Reilly, et al.
Cancer Chemotherapy and Pharmacology
|
September 5, 2019
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, et al.
Drugs in Context
|
December 20, 2016
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, et al.
Cancer Medicine
|
April 3, 2021
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
James J Harding, Richard K Do, Amin Yaqubie, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer
Christopher J Sweeney, Chris H Takimoto, Jane E Latz, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Pharmaceutical Statistics
|
January 7, 2020
Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs
Claire L Smith, Zachary Thomas, Nathan Enas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
Yun Oh, Roy S Herbst, Howard Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2005
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors
Gary K Schwartz, Aaron Weitzman, Eileen O'Reilly, et al.
Cancer Chemotherapy and Pharmacology
|
September 5, 2019
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, et al.
Drugs in Context
|
December 20, 2016
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, et al.
Cancer Medicine
|
April 3, 2021
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
James J Harding, Richard K Do, Amin Yaqubie, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer
Christopher J Sweeney, Chris H Takimoto, Jane E Latz, et al.
Page
of 2